CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer

This study has been completed.

Study NCT00028028 Information provided by Eastern Cooperative Oncology Group

First Received: December 7, 2001 Last Updated: January 26, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	January 2007 (Final data collection date for primary outcome measure)

Publications:

Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group (E1500). A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007 Nov;2(11):1036-41.

Pandya KJ, Levy DE, Hidalgo M, et al.: A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. [Abstract] J Clin Oncol 23 (Suppl 16): A-7005, 622s, 2005.